CN109535249A - A kind of monoclonal antibody ZKns3G2 and its application - Google Patents
A kind of monoclonal antibody ZKns3G2 and its application Download PDFInfo
- Publication number
- CN109535249A CN109535249A CN201811519058.1A CN201811519058A CN109535249A CN 109535249 A CN109535249 A CN 109535249A CN 201811519058 A CN201811519058 A CN 201811519058A CN 109535249 A CN109535249 A CN 109535249A
- Authority
- CN
- China
- Prior art keywords
- antibody
- monoclonal antibody
- zkns3g2
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 238000003745 diagnosis Methods 0.000 claims abstract 2
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 4
- 208000001455 Zika Virus Infection Diseases 0.000 claims description 3
- 201000004296 Zika fever Diseases 0.000 claims description 3
- 208000035332 Zika virus disease Diseases 0.000 claims description 3
- 208000020329 Zika virus infectious disease Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 abstract description 9
- 101500010375 Zika virus Non-structural protein 1 Proteins 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241000907316 Zika virus Species 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 11
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 101710128560 Initiator protein NS1 Proteins 0.000 description 9
- 101710144127 Non-structural protein 1 Proteins 0.000 description 9
- 210000001806 memory b lymphocyte Anatomy 0.000 description 9
- 239000000975 dye Substances 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 206010012310 Dengue fever Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 208000025729 dengue disease Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 208000001490 Dengue Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 102100030704 Interleukin-21 Human genes 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 1
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 1
- YSUVMPICYVWRBX-VEVYYDQMSA-N Arg-Asp-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YSUVMPICYVWRBX-VEVYYDQMSA-N 0.000 description 1
- FEZJJKXNPSEYEV-CIUDSAMLSA-N Arg-Gln-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FEZJJKXNPSEYEV-CIUDSAMLSA-N 0.000 description 1
- SSZGOKWBHLOCHK-DCAQKATOSA-N Arg-Lys-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N SSZGOKWBHLOCHK-DCAQKATOSA-N 0.000 description 1
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
- QMQZYILAWUOLPV-JYJNAYRXSA-N Arg-Tyr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CC1=CC=C(O)C=C1 QMQZYILAWUOLPV-JYJNAYRXSA-N 0.000 description 1
- YQPSDMUGFKJZHR-QRTARXTBSA-N Asn-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)N YQPSDMUGFKJZHR-QRTARXTBSA-N 0.000 description 1
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 1
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 1
- XUZQMPGBGFQJMY-SRVKXCTJSA-N Gln-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N XUZQMPGBGFQJMY-SRVKXCTJSA-N 0.000 description 1
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 1
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 1
- XKPACHRGOWQHFH-IRIUXVKKSA-N Gln-Thr-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XKPACHRGOWQHFH-IRIUXVKKSA-N 0.000 description 1
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 1
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 1
- KRRMJKMGWWXWDW-STQMWFEESA-N Gly-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KRRMJKMGWWXWDW-STQMWFEESA-N 0.000 description 1
- LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 description 1
- ULZCYBYDTUMHNF-IUCAKERBSA-N Gly-Leu-Glu Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ULZCYBYDTUMHNF-IUCAKERBSA-N 0.000 description 1
- LRQXRHGQEVWGPV-NHCYSSNCSA-N Gly-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN LRQXRHGQEVWGPV-NHCYSSNCSA-N 0.000 description 1
- LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 1
- SFOXOSKVTLDEDM-HOTGVXAUSA-N Gly-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CN)=CNC2=C1 SFOXOSKVTLDEDM-HOTGVXAUSA-N 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- OVPYIUNCVSOVNF-ZPFDUUQYSA-N Ile-Gln-Pro Natural products CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O OVPYIUNCVSOVNF-ZPFDUUQYSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- USTCFDAQCLDPBD-XIRDDKMYSA-N Leu-Asn-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N USTCFDAQCLDPBD-XIRDDKMYSA-N 0.000 description 1
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 1
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 1
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 1
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 1
- 101710088839 Replication initiation protein Proteins 0.000 description 1
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- HBTCFCHYALPXME-HTFCKZLJSA-N Ser-Ile-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HBTCFCHYALPXME-HTFCKZLJSA-N 0.000 description 1
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 1
- XOWKUMFHEZLKLT-CIQUZCHMSA-N Thr-Ile-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O XOWKUMFHEZLKLT-CIQUZCHMSA-N 0.000 description 1
- YJCVECXVYHZOBK-KNZXXDILSA-N Thr-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H]([C@@H](C)O)N YJCVECXVYHZOBK-KNZXXDILSA-N 0.000 description 1
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 1
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 1
- IJVNLNRVDUTWDD-MEYUZBJRSA-N Thr-Leu-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IJVNLNRVDUTWDD-MEYUZBJRSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- DXYWRYQRKPIGGU-BPNCWPANSA-N Tyr-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DXYWRYQRKPIGGU-BPNCWPANSA-N 0.000 description 1
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 1
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 1
- KYPMKDGKAYQCHO-RYUDHWBXSA-N Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 KYPMKDGKAYQCHO-RYUDHWBXSA-N 0.000 description 1
- UMSZZGTXGKHTFJ-SRVKXCTJSA-N Tyr-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UMSZZGTXGKHTFJ-SRVKXCTJSA-N 0.000 description 1
- MWUYSCVVPVITMW-IGNZVWTISA-N Tyr-Tyr-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 MWUYSCVVPVITMW-IGNZVWTISA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- GBESYURLQOYWLU-LAEOZQHASA-N Val-Glu-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N GBESYURLQOYWLU-LAEOZQHASA-N 0.000 description 1
- MYLNLEIZWHVENT-VKOGCVSHSA-N Val-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](C(C)C)N MYLNLEIZWHVENT-VKOGCVSHSA-N 0.000 description 1
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 1
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention belongs to field of biotechnology, and in particular to a kind of monoclonal antibody ZKns3G2 and its application.Monoclonal antibody ZKns3G2 provided by the invention is a kind of full human monoclonal antibody for zika virus NS1 albumen, including with amino acid sequence shown in SEQ ID NO.1 heavy chain variable domain and SEQ ID NO.2 shown in amino acid sequence light chain variable region.Heavy chain and light chain in monoclonal antibody ZKns3G2 provided by the invention are nature pairings, therefore the affinity of antibody is high.In conjunction with zika virus NS1 protein-specific, do not intersect with dengue virus NS 1, can be used as diagnosis or therapeutic antibodies.
Description
Technical field
The invention belongs to field of biotechnology, and in particular to a kind of monoclonal antibody ZKns3G2 and its application.
Background technique
2015 to 2016 zika virus (ZIKV) world wide especially America area rapidly propagate, because it can
Lead to serious birth defect and adult neural's complication, international public health emergency is declared as by WHO.
ZIKV is equally propagated through yellow-fever mosquito, often appears in the Endemic Area dengue virus (DENV).ZIKV and DENV are often appeared in together
One area, but Clinical symptoms, harm and disposition are different.Urgent need distinguishes both virus infections as early as possible, especially to the woman of pregnancy
For female.ZIKV and DENV belongs to flavivirus, and affiliation is close.Due to the phase on genome and protein sequence and conformation
Like caused cross reaction, difficulty is brought to distinguish both virus infections.
Serum polyclonal antibody and the monoclonal antibody separated from the infected are studies have shown that ZIKV induction host's generation is directed to disease
There are extensive cross reactions for malicious memebrane protein E antibody.And high special is presented for the antibody of virus nonstructural protein 1 (NS1)
Property reaction, provide possibility to identify both virus infections.Balmaseda etc. (2017) is separated with from ZIKV the infected
Only in conjunction with ZIKV NS1 monoclonal antibody, the Inhibition ELISA based on NS1 is established, is used for ZIKV Infect And Diagnose, and distinguish other Huangs
Virus such as 4 serotypes of Dengue, west nile virus and yellow fever virus.
It there is no effective vaccine for ZIKV at present, more lack early diagnosis and effective treatment method.NS1 albumen exists
It plays an important role in flavivirus life cycle, including virus replication, immunologic escape and the effect in pathogenic mechanism.?
NS1 is specified to play an important role in dengue fever pathogenesis, it is related to the seriousness of disease.Therefore it is directed to zika virus NS1
Full people's monoclonal antibody of albumen is likely to become a kind of strategy of zika virus disease treatment.
The technology of preparing of monoclonal antibody experienced the hybridoma technology of source of mouse antibody, mouse people's chimeric antibody, mouse antibody source of people skill
Then there is people's monoclonal antibody technology of preparing in art.It is presently available for the predominantly phage display skill of extensive specificity antibody screening
Art and single B cell antibody technology.Display technique of bacteriophage can be used for screening Separated pin to the antibody of any target antigen.However
The specific antibody filtered out from the heavy chain of random combine antibody and light chain library, heavy chain and light chain pairing are not that nature produces
Raw antibody is original, influences the affinity and function of antibody.Single B cell antibody technology directly expands antibody from single B cell
The variable region gene of heavy chain and light chain constructs antibody expressing plasmid, antibody is then expressed in cell culture system.This skill
Art is separable to be primarily present the functional antibodies that conformation is special in the infected's body.
Chinese patent application CN107188935A discloses a kind of zika virus NS1 antigenic mutant and its application, this is anti-
Former mutant is by carrying out knock out mutants to the high segment of homology, then through gene chemical synthesis, vector construction, protokaryon table
It reaches, antigen purification and immunologic function Analysis and Screening obtain, and have the function of reducing Dengue positive sample recall rate.But
This antigenic mutant mutation rate is low, is only reduction of zika virus and intersects with what dengue virus antibody detected, can not eradicate.
In summary, it is low that specificity exists in the prior art, can not thoroughly distinguish zika virus and dengue virus, screens
The disadvantages of process is cumbersome.
Summary of the invention
It is an object of the invention to overcome shortcoming and deficiency existing in the prior art, a kind of monoclonal antibody is provided
ZKns3G2 and its application.Monoclonal antibody ZKns3G2 provided by the invention has affinity high, can be used for distinguishing zika virus
And the advantages of dengue virus infection.
Currently, there is no effective vaccine for this sick new infections disease of zika virus, more lack early diagnosis and
Effective treatment method.The present invention screens by the culture to finite population memory B cell and obtains heavy chain of antibody and light chain
Variable region gene, construct antibody expression vector, antibody is then expressed in cell culture system.This method is suitable for building
Full human monoclonal antibody.
In order to achieve the above object, the present invention provides a kind of monoclonal antibody ZKns3G2, including heavy chain and light chain, institutes
The amino acid sequence information of the Variable Area of heavy chain is stated as shown in SEQ ID NO.1；The amino acid of the Variable Area of the light chain
Sequence information is as shown in SEQ ID NO.2；
EVQLLESGGGLIQPGGSLRLSCAASGLTVSNNYMNWVRQAPGKGLEWV SIIYSSGSTYYADSVKGRF
TISRDTRKNTLYLQMHSLRVEDTAVYYCARYRGW L(SEQ ID NO.1)；
VIWMTQSPSSLSASVGDRVTITCRASQSVSSHLNWYQQKPGKAPKLLIY AVSSLQSGVPSRFSGGDS
GTDFTLTIASLQPEDFATYYCQQTYTIPRTFGQGTK VEIK(SEQ ID NO.2)。
The present invention also provides a kind of Variable Area for encoding the heavy chain or the amino acid of the Variable Area of above-mentioned light chain
The polynucleotide sequence of sequence；The polynucleotide sequence of the heavy chain variable domain is encoded as shown in SEQ ID NO.3, is compiled
The polynucleotide sequence of the code light chain variable region is as shown in SEQ ID NO.4；
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGATCCAGCCTGGGGG GTCCCTGAGACTCTCCTGTG
CAGCCTCTGGGCTCACCGTCAGTAACAACTA CATGAACTGGGTCCGCCAGGCTCCAGGAAAGGGGCTGGAGTGGG
TCTCAA TTATTTATAGTAGTGGTAGCACGTACTACGCAGACTCCGTGAAGGGCCGCTT CACCATCTCCAGAGAC
ACTCGCAAGAACACTCTGTATCTTCAAATGCACAG CCTGAGAGTCGAGGACACGGCCGTATATTACTGTGCGAGA
TACCGCGGCTG GCTTGACTACTGGGGCCAGGGAACCCTGGTCACTGTCTCCTCAG(SEQ ID NO.3)；
GTCATCTGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGA GACAGAGTCACCATCACTT
GTCGGGCAAGTCAGAGCGTTAGCAGCCATTT AAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAACTCCTGA
TCTATG CTGTGTCCAGTTTACAAAGTGGGGTCCCATCAAGGTTCAGTGGCGGTGAT TCTGGCACAGATTTCACT
CTCACCATCGCCAGTTTGCAACCTGAAGACTTT GCAACTTACTACTGTCAACAGACTTACACTATCCCTCGGACG
TTCGGCCAA GGGACCAAGGTGGAAATCAAAC(SEQ ID NO.4)。
The monoclonal antibody ZKns3G2's the preparation method comprises the following steps:
S1, it is screened from the infected's peripheral blood mononuclear cells using fluorescence antibody, obtains memory B cell；
S2, the resulting memory B cell of incubation step S1 are added cell factor and are converted using EBV, using capture
ELISA screens the presence of antibody in B cell culture supernatant, obtains the B cell containing positive antibody；
The RNA of S3, the resulting B cell of extraction step S2, reverse transcription is at cDNA, heavy chain and light chain through PCR amplification antibody
Variable region is cloned on antibody expression vector, obtains the expression vector of the ZKns2E11 containing monoclonal antibody；The PCR primer and
PCR amplification program is shown in document (J Immunol Methods.2008 Jan 1；329(1-2):112-24.)；
S4, the expression vector of the resulting ZKns2E11 containing monoclonal antibody of step S3 is transfected to 293T cell, 5-6 days
Afterwards, collect supernatant to get.
Preferably, the fluorescence antibody in the step S1 includes IgD-FITC, CD19-ECD, CD27-PC7, CD38-
APCA750, IgM-PB and CD45-KO.
Preferably, the Porcine HGF in the step S2 includes the health that CpG, IL21, IL2 and radiating irradiation are crossed
The cell (PBMC) of human peripheral monokaryon.
The present invention also provides a kind of monoclonal antibody ZKns3G2 in preparation clinical diagnosis or treatment zika virus disease
Application.
Compared with prior art, monoclonal antibody ZKns3G2 provided by the invention, has the advantage that
(1) monoclonal antibody ZKns3G2 provided by the invention is obtained through B cell culture binding antibody clone technology
Target full people's monoclonal antibody ZKns3G2 of zika virus NS1 albumen；
(2) monoclonal antibody ZKns3G2 provided by the invention, the heavy chain and light chain for being included are nature pairings, therefore anti-
The affinity of body is very high；
(3) monoclonal antibody ZKns3G2 provided by the invention zika virus specificity with higher, can be by stockaded village's card disease
Poison and dengue virus separate；
(4) monoclonal antibody ZKns3G2 provided by the invention is that one kind can separate and exist and be difficult in vitro in vivo
The functional antibodies of the conformational domains imitated.
Detailed description of the invention
Fig. 1 is the structural schematic diagram of the heavy chain expression vector of monoclonal antibody ZKns3G2；
Fig. 2 is the structural schematic diagram of the light chain expression vector of monoclonal antibody ZKns3G2；
Fig. 3 is the result figure of the association reaction of monoclonal antibody ZKns3G2 and virus N S1 albumen；
Fig. 4 is ZKns3G2 affinity measurement result figure；
Fig. 5 is the result figure that ZKns3G2 prepares that colloid gold test paper detects recombinant virus NS1 albumen.
Specific embodiment
The present invention is further explained combined with specific embodiments below, it is noted that following embodiment is only
To explain the present invention, and it cannot be used to limit the present invention, all technical solutions same or similar with the present invention are in this hair
Within bright protection scope.Unless otherwise specified, what technological means used in embodiment was well known to those skilled in the art
Conventional means, raw materials used is commercial goods.
Fluorescence antibody, antibody expression vector and flow cytometer are purchased from Beckman Coulter Inc., the U.S.
(Beckman Coulter,Inc.)；CDNA synthetic agent box (SuperScript III First Strand Synthesis
System, invitrogen, #18080051) it is purchased from Shanghai Yu Bo Biotechnology Co., Ltd；Antibody expression vector is shown in text
Offer (J Immunol Methods.2008 Jan 1；329(1-2):112-24.).
The preparation of 1 monoclonal antibody ZKns3G2 of embodiment
1. the identification and sorting of memory B cell
The separation of 1.1 peripheral blood mononuclear cells: stockaded village's card the infected's convalescence peripheral vein EDTA anticoagulation is taken, utilization is close
Spend gradient centrifugation procedure separating peripheral blood mononuclear cells, packing 5 × 106/ pipe, is placed in liquid nitrogen and freezes；
The dyeing of 1.2 fluorescent labeled antibodies: peripheral blood mononuclear cells is placed in water-bath in 37 DEG C and dissolves, and is buffered using PBS
Liquid washs 3 times, is subsequently added into antibody and is dyed, and room temperature, which is protected from light, is incubated for 15min, after washing using PBS buffer solution, is added 400
μ L PBS buffer solution suspension cell up flow type instrument, the streaming instrument are Beckman Kurt MoFlo Astrios EQ ultrahigh speed
Fluidic cell separation system；
If 9 analyzer tubes, such as table 1, the antibody of corresponding single fluorescent marker is added in 1-7 pipe, and 7 kinds of mixing are added in the 9th pipe
Fluorescent marker antibody, the 8th pipe for only cell blank tube, sample cell with the 9th pipe equally dyes；
The sorting of 1.3 memory B cells: machine is analyzed on sample cell, and the CD45 positive living is irised out according to 7-AAD and CD45
Leucocyte.B cell is irised out according to CD19.IgD-IgM-CD27+CD38low is defined in the B cell group of IgM and IgD jack to jack adapter
Group is memory B cell.Memory B cell is sorted into 96 porocyte culture plates containing cell culture fluid, 25-50 cell/every
Hole.
The classification for the fluorescent labeled antibody that 1 1-7 pipe of table is added
| Guan Hao | Dyeing pipe setting | The fluorescence of antibody and label | Volume (μ L) | Fluorescence channel |
| 1 | Single dye | IgD-FITC | 10 | FL1 |
| 2 | Single dye | CD19-ECD | 5 | FL3 |
| 3 | Single dye | 7-AAD | 10 | FL4 |
| 4 | Single dye | CD27-PC7 | 5 | FL5 |
| 5 | Single dye | CD38-APC A750 | 2 | FL8 |
| 6 | Single dye | IgM-PB | 5 | FL9 |
| 7 | Single dye | CD45-KO | 5 | FL10 |
| 8 | Blank tube | Antibody is not added | ||
| 9 | Sample cell | 7 kinds of antibody mixed liquors |
2. memory B cell culture and the screening of culture supernatant antibody.
The Healthy People that CpG, IL21, IL2, radiating irradiation are crossed is added into 96 porocyte culture plates containing memory B cell
PBMC and B95.8 cells and supernatant culture 7-10 days containing EBV.With needle in capture ELISA screening B cell culture supernatant
Presence to zika virus NS1 protein antibodies.
3. the clone of antibody
3.1cDNA synthesis: for having in the supernatant that filters out for B cell existing for zika virus NS1 protein antibodies,
It first proposes RNA another mistake and is transcribed into cDNA.CDNA synthesizes kit (SuperScript III First Strand Synthesis
System,invitrogen,#18080051)。
The heavy chain and light-chain variable region gene of 3.2 nested PCR amplification antibody: PCR primer sequence bibliography (J
Immunol Methods.2008 Jan 1；329 (1-2): 112-24.), reaction uses the super fidelity dna polymerase of Phusion
(Phusion High-Fidelity PCR Master Mix with GC Buffer,NEB,#M0532s)。
The heavy chains of 3.3 antibody and light chain variable region PCR product through digestion (VH, AgeI/SalI, VK, AgeI/Xhol, VL,
AgeI/BsiWI it) is cloned on the antibody expression vector containing human IgG1's constant region, heavy chain expression vector is shown in that Fig. 1, human IgG1 are permanent
The antibody expression vector for determining area is shown in Fig. 2.The heavy chain measured and light-chain variable region gene sequence are analyzed through IMGT/V-Quest.
The specificity analysis of 2 antibody of embodiment
1. the production of antibody: the heavy chain for the antibody that the sequence of building determines and light chain vector cotransfection are entered into 293T cell,
The culture supernatant containing antibody is harvested after 5-6 days；
2. the culture supernatant containing antibody is carried out the affine column purification of proteinA by the purifying of antibody, and measures protein content；
3. the reaction of antibody: antibody and zika virus (ZIKA) and dengue virus 1-4 type (DENV1, DENV2, DENV3,
DENV4) the association reaction of NS1 albumen, using capture NS1 antigen ELISA method, reaction result is shown in Fig. 3；
4. affinity of antibody measures (BLI): using the Octet RED384 system of Fortebio company, selecting Anti-
Human IgG Fc (AHC) sensor, affinity testing result are shown in Fig. 4, wherein affinity size constant KD is 4.62E-10,
Binding constant Ka is 5.57E+0.5, and dissociation constant Kd is 2.57E-0.4；Using antibody as Ligand, first curing antibody to biography
On sensor (20 μ g/mL of concentration)；Antigen detects the association and dissociation ability of antibody and antigen, detection recombination disease as analyte
Malicious NS1 albumen result is shown in Fig. 5.
Finally it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention rather than protects to the present invention
The limitation of range is protected, although elaborating referring to preferred embodiment to the present invention, those skilled in the art should
Understand, it can be with modification or equivalent replacement of the technical solution of the present invention are made, without departing from the essence of technical solution of the present invention
And range.
Sequence table
<110>Guangzhou City No.8 People's Hospital
<120>a kind of monoclonal antibody ZKns3G2 and its application
<130> 2018.11.29
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 102
<212> PRT
<213>zika virus heavy chain of antibody amino acid sequence (Zika virus anti-weight chain amino acid
sequence)
<400> 1
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Asn Asn
20 25 30
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ile Ile Tyr Ser Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Thr Arg Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met His Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Tyr Arg Gly Trp Leu
100
<210> 2
<211> 107
<212> PRT
<213>zika virus antibody light chain amino acid sequence (Zika virus anti-weight chain amino acid
sequence)
<400> 2
Val Ile Trp Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Ser Ser His
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Val Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Gly Asp Ser Gly Thr Asp Phe Thr Leu Thr Ile Ala Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Thr Ile Pro Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 3
<211> 346
<212> DNA
<213>polynucleotide sequence (the Polynucleotide sequences of zika virus heavy chain of antibody amino acid is encoded
encoding Zika virus anti-weight chain amino acids)
<400> 3
gaggtgcagc tgttggagtc tgggggaggc ttgatccagc ctggggggtc cctgagactc 60
tcctgtgcag cctctgggct caccgtcagt aacaactaca tgaactgggt ccgccaggct 120
ccaggaaagg ggctggagtg ggtctcaatt atttatagta gtggtagcac gtactacgca 180
gactccgtga agggccgctt caccatctcc agagacactc gcaagaacac tctgtatctt 240
caaatgcaca gcctgagagt cgaggacacg gccgtatatt actgtgcgag ataccgcggc 300
tggcttgact actggggcca gggaaccctg gtcactgtct cctcag 346
<210> 4
<211> 322
<212> DNA
<213>polynucleotide sequence (the Polynucleotide sequences of zika virus antibody light chain amino acid is encoded
encoding Zika virus anti-weight chain amino acids)
<400> 4
gtcatctgga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgtc gggcaagtca gagcgttagc agccatttaa attggtatca gcagaaacca 120
gggaaagccc ctaaactcct gatctatgct gtgtccagtt tacaaagtgg ggtcccatca 180
aggttcagtg gcggtgattc tggcacagat ttcactctca ccatcgccag tttgcaacct 240
gaagactttg caacttacta ctgtcaacag acttacacta tccctcggac gttcggccaa 300
gggaccaagg tggaaatcaa ac 322
Claims (4)
1. a kind of monoclonal antibody ZKns3G2, including heavy chain and light chain, which is characterized in that the amino of the heavy chain variable domain
Acid sequence is SEQ ID NO.1；The amino acid sequence of the light chain variable region is SEQ ID NO.2.
2. monoclonal antibody ZKns3G2 as described in claim 1, which is characterized in that encode the heavy chain Variable Area or
The amino acid sequence of the Variable Area of light chain is polynucleotide sequence.
3. monoclonal antibody ZKns3G2 as claimed in claim 2, which is characterized in that encode the Variable Area of the heavy chain
Polynucleotide sequence encodes the polynucleotide sequence such as SEQ of the Variable Area of the light chain as shown in SEQ ID NO.3
Shown in ID NO.4.
4. monoclonal antibody ZKns3G2 as described in claim 1, the application in preparation diagnosis or treatment zika virus disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811519058.1A CN109535249B (en) | 2018-12-12 | 2018-12-12 | Monoclonal antibody ZKns3G2 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811519058.1A CN109535249B (en) | 2018-12-12 | 2018-12-12 | Monoclonal antibody ZKns3G2 and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109535249A true CN109535249A (en) | 2019-03-29 |
| CN109535249B CN109535249B (en) | 2021-06-01 |
Family
ID=65855118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811519058.1A Active CN109535249B (en) | 2018-12-12 | 2018-12-12 | Monoclonal antibody ZKns3G2 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109535249B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113122659A (en) * | 2021-04-27 | 2021-07-16 | 北京瀚梅生物科技有限公司 | Kit for detecting virus |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106279409A (en) * | 2016-08-10 | 2017-01-04 | 中国科学院微生物研究所 | A kind of zika virus human monoclonal antibody and application thereof |
| CN106456732A (en) * | 2014-04-15 | 2017-02-22 | 索伦托治疗有限公司 | Antigen binding proteins that bind WISP1 |
| CN106478815A (en) * | 2016-10-19 | 2017-03-08 | 广州市第八人民医院 | Quickly prepare the zika virus specifically method of full human monoclonal antibody and application |
| US20170088620A1 (en) * | 2015-09-29 | 2017-03-30 | Amgen Inc. | Asgr inhibitors |
-
2018
- 2018-12-12 CN CN201811519058.1A patent/CN109535249B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106456732A (en) * | 2014-04-15 | 2017-02-22 | 索伦托治疗有限公司 | Antigen binding proteins that bind WISP1 |
| US20170088620A1 (en) * | 2015-09-29 | 2017-03-30 | Amgen Inc. | Asgr inhibitors |
| CN106279409A (en) * | 2016-08-10 | 2017-01-04 | 中国科学院微生物研究所 | A kind of zika virus human monoclonal antibody and application thereof |
| CN106478815A (en) * | 2016-10-19 | 2017-03-08 | 广州市第八人民医院 | Quickly prepare the zika virus specifically method of full human monoclonal antibody and application |
Non-Patent Citations (4)
| Title |
|---|
| JIMENEZ GOMEZ,G.等: ""immunoglobulin heavy chain variable region, partial [Homo sapiens]"", 《GENBANK》 * |
| XIUJIE GAO 等: ""Delayed and highly specific antibody response to nonstructural protein 1 (NS1) revealed during natural human ZIKV infection by NS1-based capture ELISA"", 《BMC INFECT DIS》 * |
| XIUJIE GAO 等: ""High specificity of human antibody response to nonstructural protein NS1 elicited by Zika virus infection"", 《J IMMUNOL》 * |
| 高秀洁: ""寨卡病毒感染宿主NS1抗体反应特征及单克隆抗体在早期诊断中的应用"", 《中国博士学位论文全文数据库(电子期刊) 医药卫生科技辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113122659A (en) * | 2021-04-27 | 2021-07-16 | 北京瀚梅生物科技有限公司 | Kit for detecting virus |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109535249B (en) | 2021-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105461805B (en) | Monoclonal Antibodies against Porcine Epidemic Diarrhea Virus and its application | |
| CN112250763B (en) | Antibody targeting SARS-CoV-2 coronavirus and its diagnosis and detection use | |
| CN105527437B (en) | A kind of detection kit and its application | |
| Weitkamp et al. | Infant and adult human B cell responses to rotavirus share common immunodominant variable gene repertoires | |
| CN106211773A (en) | Antibody molecule and application thereof for dengue virus | |
| CN110964102B (en) | Monoclonal antibody capable of simultaneously combining with canine, feline and mink parvoviruses, variable region sequence thereof, hybridoma cell strain and application | |
| CN109232734B (en) | Monoclonal antibody specifically binding canine adenovirus, pharmaceutical composition, kit and application thereof | |
| CN105695420A (en) | Mouse bone marrow hybridoma cell strains, monoclonal antibody generated by same and application | |
| CN110028579A (en) | A kind of monoclonal antibody and its application of anti-Nipah virus envelope glycoprotein | |
| CN109232736A (en) | Specifically bind monoclonal antibody, pharmaceutical composition, kit and its application of transmissible gastro-enteritis virus | |
| CN107344968A (en) | A kind of time-resolved fluorescence immunoassay method for being used to detect avian influenza virus H7N9 | |
| TW200526959A (en) | Method for detection of hepatitis virus C | |
| CN104407145B (en) | Enterovirns type 71 latex agglutination assay kit preparations and applicatio | |
| CN101597334A (en) | Monoclonal antibody of bluetongue virus (BTV) and preparation method and application | |
| CN112661841B (en) | Fully human monoclonal antibody 17-2 for neutralizing neoepitope of new coronavirus and application thereof | |
| CN109535249A (en) | A kind of monoclonal antibody ZKns3G2 and its application | |
| CN107098968B (en) | Monoclonal antibody mAb910 and its application | |
| BR112020015475A2 (en) | CONNECTING MOLECULE HAVING NEUTRALIZATION ACTIVITY AGAINST THE CORONAVIRUS THAT CAUSES THE MIDDLE EAST RESPIRATORY SYNDROME | |
| CN109180810A (en) | Specifically bind norovirus GI.1 genotype VP1 albumen and/or the antibody of VLP and its preparation method and application | |
| CN109553680A (en) | A kind of monoclonal antibody ZKns4B8 and its application | |
| CN109503712A (en) | A kind of monoclonal antibody ZKns2E11 and its application | |
| CN106226520A (en) | Antigen of mycobacterium tuberculosis albumen Rv0865 and the application of B cell epitope peptide thereof | |
| Ebrahimzade et al. | Isolation of small number of Cryptosporidium parvum oocyst using immunochromatography | |
| Zhou et al. | High throughput screening of scFv antibodies against viral hemorrhagic septicaemia virus by flow cytometry | |
| CN100519759C (en) | A process for preparation of an agglutination reagent for rapid detection of typhoid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |